18 results about "Morphine" patented technology

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

The application provides a method for detecting psychotropic drugs in environmental sludge based on acid pretreatment, which comprises the following steps: S1: obtaining a sludge sample to be detected, performing pressurized fluid extraction on the sludge sample to be detected after freeze-drying to obtain an extraction solution, performing solid-phase extraction on the extraction solution to obtain an eluate, and redissolving the eluate to obtain a solution to be detected, wherein the pressurized fluid extraction is performed under the condition of 5 ‰ formic acid water without heating; and S2: performing liquid chromatography mass spectrometry on the solution to be detected to obtain a mass spectrum, wherein the psychotropic drug is one of eptazocine, codeine, AMP, MAMP, MDA, monoacetylmorphine, MDMA, PMMA, fentanyl, norfentanyl, ketamine, norfentanyl, benzoyl eptazocine, cocaine and tramadol, and the method realizes detection of multiple psychotropic drugs in environmental sludge.

The invention relates to the technical field of medicines, and discloses a novel light cuspidine type diterpenoid alkaloid compound and application of the novel light cuspidine type diterpenoid alkaloid compound. According to the present invention, the novel C20 selaginine type diterpenoid alkaloids such as the Carmaloidline C, the Carmaloidline D and the Aconialoidline C, which are provided by the present invention, all have significant analgesic effects; wherein the analgesic activity of the Carmaloidline C is the strongest, is superior to that of the positive drug morphine and is obviously superior to that of the positive drug ibuprofen, and the analgesic activity of the Carmaloidline D and the analgesic activity of the Aponiloidline C are superior to that of the positive drug ibuprofen. The medicines can be used for developing analgesic medicines for various acute or chronic pains.

A method, apparatus and computer program product are provided for a compiled standardized measure representative of a subset of prescription transactions associated with a controlled substance. The compiled standardized measures may be used in the prescription domain to notify prescribers of a patient's morphine milligram equivalent (MME) to reduce risks related to drug overdose, abuse, and the like. Historical prescription transactions may be accessed to identify prescriptions classified as an opioid or other controlled substance, and that may likely still be in a patient's possession based upon days supply, such that a daily MME may be calculated. Messaging is provided to the prescriber if the amount exceeds a maximum threshold, and the prescription can be changed accordingly.

The invention discloses a method for measuring morphine content in a cough-relieving and phlegm-reducing pill, and aims to improve the quality standard of the cough-relieving and phlegm-reducing pill and guarantee the medication safety of a patient. The method adopts a high performance liquid chromatography and comprises the following steps: precisely weighing a cough-relieving and phlegm-reducing pill sample, grinding, and carrying out ultrasonic extraction by taking 20% methanol containing 5% glacial acetic acid as an extraction solvent to prepare a test solution; preparing a morphine reference substance solution; according to the method, octadecylsilane chemically bonded silica is taken as a filling agent, acetonitrile and a specific mixed solution are taken as a mobile phase for gradient elution, and determination is carried out under the conditions that the column temperature is 30 DEG C and the detection wavelength is 210 nm. The method is verified by specificity, accuracy, repeatability and the like, the result is reliable, the linear relation is good, a low-toxicity organic reagent is used, the method is environment-friendly, the method can be used as a quality control means of Chinese patent medicines containing poppy shells, and the blank of morphine content determination in the existing standard is filled.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The invention belongs to the technical field of medicine, and particularly discloses a preparation method and application of anacycline alkali C and D. The preparation method comprises the following steps: extracting anacycline root medicinal materials by using a mixed solution of acetone and methanol, dissolving by using a hydrochloric acid solution, extracting by using ethyl acetate, adding a saturated sodium bicarbonate solution into an ice-water bath to adjust the pH value, filtering, washing, and drying to obtain the anacycline alkali C and the anacycline alkali D. The preparation method comprises the following steps: extracting the anacycline alkali C and the anacycline alkali D; an alkalized solution is obtained; fully extracting with ethyl acetate and n-butyl alcohol in sequence to obtain crude alkaloid; performing multi-step separation and purification through silica gel column chromatography, MCI gel, Sephadex LH-20 column chromatography, semi-preparative HPLC (High Performance Liquid Chromatography) and the like, and finally performing forward HPLC chiral resolution to obtain a target compound. Activity research shows that the anacycline C and the anacycline D have a remarkable inhibiting effect on mouse writhing reaction caused by acetic acid under the dosage of 5mg / kg, and the analgesic effect of the anacycline C under the dosage of 1mg / kg and 0.2 mg / kg is superior to that of morphine, so that the anacycline C and the anacycline D can be used as novel analgesic lead compounds with development potential.

The invention belongs to the field of medicines, and discloses pyrimido imidazolone derivatives as well as a preparation method and medical application thereof. The pyrimidino imidazolone derivative has a structure as shown in a general formula I. The preparation method comprises the following steps: carrying out substitution reaction on 1-(4-methoxyphenyl)-1-R2-methylamine and a compound 1 under the catalysis of an organic base to obtain a compound 2; carrying out Dieckmann condensation reaction on the compound 2 and excessive CDI to obtain a compound 3; and carrying out Suzuki coupling reaction on the compound 3 and different substituted arylboronic acid or morpholine under the catalysis of sodium carbonate, Pd (OAc) 2 and TPPTS to obtain the pyrimido imidazolone derivative. The pyrimido imidazolone derivative selectively has a strong inhibition effect on proliferation of tumor cells of lung cancer, prostatic cancer, colon cancer, breast cancer, liver cancer and the like, and can be applied to preparation of medicines for treating and / or preventing malignant tumors.

The invention relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit. Endophalin is also called as brain endophine, is a morphine-like biochemical synthetic hormone and is secreted by pituitary gland. Beta-enorphin is small in molecular weight and poor in immunogenicity and has various structural analogues, so that when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. The invention mainly relates to the design and synthesis of a beta-enorphin hapten, the preparation of a beta-enorphin complete antigen and an anti-beta-enorphin antibody, a method for measuring the concentration of beta-enorphin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a beta-ennorphin derivative. The beta-ennorphin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

A system and methods for medication management and incentivized compliance using a distributed ledger are disclosed. A medication dispenser with a lock, weight sensor, and control unit communicates with a blockchain network executing smart contracts that authorize dispensing events, record authenticated telemetry, and account for tokenized dose entitlements normalized in morphine-milligram equivalents (MME). A prescriber device assigns entitlements to a patient wallet; the dispenser unlocks only upon receipt of an on-chain authorization event that cryptographically binds the requested dose to measured inventory and policy constraints. Post-dispense, signed weight deltas are committed to an authenticated store for audit. Optional risk scoring derived from historical usage features gates dispensing or escalates to multi-party authorization. Unused entitlements may be reconciled under policy via redemption logic. The architecture reduces diversion by coupling cryptographic authorization with tamper-evident telemetry and immutable audit trails.

Provided are very slightly soluble salts of apomorphine, sustained-release pharmaceutical compositions including the slightly or very slightly soluble salts of apomorphine, and their uses in treating a neurological disease, sexual dysfunction, neuroleptic (-like) malignant syndrome, or an alcohol-related disorder. The very slightly soluble salts of apomorphine are an apomorphine hydroxynaphthoate salt or an apomorphine pamoate salt in a crystal or amorphous form. Also provided are methods for preparing the very slightly soluble salt of apomorphine and its crystal or amorphous form.

The invention relates to a method of treating a neurological disorder in which an increase in dopaminergic turnover is beneficial, the method comprising intranasal administration of an encapsulated apomorphine composition to a subject in need thereof.

The application provides a method for detecting psychotropic drugs in environmental sludge based on alkaline pretreatment, and comprises the following steps: S1: obtaining a to-be-detected sludge sample, performing pressurized fluid extraction on the to-be-detected sludge sample after freeze-drying to obtain an extraction solution, performing solid-phase extraction on the extraction solution to obtain an elution solution, and redissolving the elution solution to obtain a to-be-detected solution, wherein the pressurized fluid extraction is performed in 1 ‰ ammonia water without heating; and S2: performing liquid chromatography mass spectrometry on the to-be-detected solution to obtain a mass spectrum, and the psychotropic drug is one of morphine, acetylfentanyl and THC-COOH or a combination of two or more thereof, so that the detection of multiple psychotropic drugs in the environmental sludge is realized.

The present invention provides a pholcodine monohydrate synthesis method, and relates to the technical field of chemical combination drug synthesis, commercially available N-(2-chloroethyl) morpholine hydrochloride and morphine base are subjected to a reaction under the alkaline action of potassium carbonate by using acetone as a solvent to obtain a pholcodine target product with high yield. And recrystallizing the crude product in deionized water to obtain a pholcodine monohydrate crystal. Through the combined action of the screening alkali and the solvent, the use of strong alkali such as sodium hydroxide is avoided, and the reaction safety is improved; in addition, through recrystallization of the product in water, not only is the pholcodine monohydrate successfully synthesized, but also the effect of further purifying the compound is achieved.

The invention belongs to the field of biological medicine, and particularly provides novel application of an imidazole pyridine derivative, and the chemical formula of the imidazole pyridine derivative is 4-{5 '-[3'-propyl-2 '-[3' '-(1' '-methyl) indolyl]-imidazole [4, 5-b] pyridine] group} morpholine. The invention provides an application of the imidazole pyridine derivative or the pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. When the compound disclosed by the invention is used for treating the pulmonary fibrosis, after animals with the pulmonary fibrosis are subjected to oral administration and inhalation administration, the lung function, the lung index, the lung tissue lesion and the fibrosis degree of model animals in different administration groups are obviously improved, so that an appropriate dosage of X22 has a treatment effect on the animals with the pulmonary fibrosis; and the pulmonary fibrosis improvement effect of the X22 inhalation way is obviously better than that of the X22 oral administration way and the existing conventional medicine.

The invention belongs to the technical field of biosensing, and relates to a portable morphine dual-mode microfluidic paper-based sensor, and a preparation method and application thereof. The sensor is integrated with a colorimetric module and an electrochemical module, and a hyaluronic acid functionalized cobalt-doped mesoporous cerium dioxide nano material (HA-coated Co-m-CeO2) is adopted as a sensing probe. The preparation method comprises the following steps: synthesizing the material, preparing a related solution, dip-dyeing filter paper with paraffin, depicting a micro-channel, pasting an electrode and dispensing a functional layer. The method has both colorimetric intuition and high electrochemical sensitivity, is low in detection limit, is simple and convenient to operate, and is suitable for rapid detection of morphine.

The present invention relates to a novel, efficient, pot- and atom-economical, and industrially applicable process for converting morphine to noroxymorphone using reagents and solvents of lesser toxicity and lower cost with respect to those used in the prior art.